Annals of Oncology Advance Access originally published online on November 22, 2005
Annals of Oncology 2006 17(5):875; doi:10.1093/annonc/mdj074
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
letter to the editor |
Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909914)
| The first 10% of the full text of this article appears below. |
We were very much interested in Norum's paper [1
] on the cost-effectiveness analysis of trastuzumab for metastatic breast cancer. The conclusion was that trastuzumab was not cost-effective in this setting. Some important points have to be discussed, which could modulate (on both sides) the results
Centre Oscar Lambret, 3 rue Frédéric Combemale, F-59000 Lille, France
* (E-mail: j-bonneterre@o-lambret.fr)